Guggenheim Reiterates Buy on InflaRx, Maintains $14 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.7%

Neg 0% Neu 88.7% Pos 0%

Guggenheim analyst Yatin Suneja reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $14 price target.

Comments

No comments yet. Be the first!